Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis
Author:
Affiliation:
1. Aarhus University Hospital; Respiratory Diseases and Allergology; Aarhus; Denmark
2. Department of Pharmacology; University of Aarhus; Aarhus; Denmark
3. Imperial College; London; England
Publisher
Wiley
Subject
Genetics (clinical),Pulmonary and Respiratory Medicine,Immunology and Allergy
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1752-699X.2012.00302.x/fullpdf
Reference75 articles.
1. The rising incidence of idiopathic pulmonary fibrosis in the U.K;Navaratnam;Thorax,2011
2. Clinical course and prediction of survival in idiopathic pulmonary fibrosis;Ley;Am J Respir Crit Care Med,2011
3. Evolving genomic approaches to idiopathic pulmonary fibrosis: moving beyond genes;Kass;Clin Transl Sci,2011
4. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management;Raghu;Am J Respir Crit Care Med,2011
5. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS);Am J Respir Crit Care Med,2000
Cited by 46 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. siTGF-β1 and pirfenidone contained Ionizable-Liposomal nanodrug for enhanced treatment of Idiopathic pulmonary fibrosis;Chemical Engineering Journal;2024-10
2. Novel inhalable powder formulation of pirfenidone with sustained release properties to improve pulmonary deposition;Journal of Drug Delivery Science and Technology;2024-04
3. No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants;Clinical and Translational Science;2024-01
4. In vivo pharmacokinetic and pharmacodynamic study of inhalable pirfenidone microparticles prepared via high-energy bead milling;Journal of Pharmaceutical Investigation;2023-11
5. Improvement of psoriatic skin lesions following pirfenidone use in patients with fibrotic lung disease;BMJ Case Reports;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3